Performance evaluation of four antibiotics using the BD Phoenix™ NMIC-413 antimicrobial susceptibility testing panel for carbapenem-resistant <i>Enterobacteriaceae</i> and carbapenem-resistant <i>Pseudomonas aeruginosa</i>.

ABSTRACT:

Background

The spread of antimicrobial resistance (AMR) poses significant threats to human health. In 2024, the World Health Organization (WHO) classified carbapenem-resistant Enterobacteriaceae (CRE) as a critical-priority pathogen and carbapenem-resistant Pseudomonas aeruginosa (CRPA) as a high-priority pathogen. This study aimed to evaluate the performance of meropenem (MEM), imipenem (IPM), cefepime (FEP), and cefoperazone/sulbactam (SCF) using the BD Phoenix™ NMIC-413 antimicrobial susceptibility testing (AST) panel (NMIC-413 panel) for CRE and CRPA at Nanfang Hospital, China.

Methods

A total of 314 archived Gram-negative clinical isolates were tested, including 219 Enterobacteriaceae isolates (150 CRE) and 95 P. aeruginosa isolates (56 CRPA)

SUBMITTER: Guan Y 

PROVIDER: S-EPMC12271110 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature